Skip to content

WOLFS PHARMA

Active Private limited companyfounded 2024active for 1 yearRue Jean-Hermesse 45, 4020 LiègeKBO/BCE: BE 1017.566.820

Lifetime

1 annual account with figures
peak of €131,915 in 2025
€131,915 
peak of €30,540 in 2025
€30,540 
peak of €40,540 in 2025
€40,540 
€468,999 
Board1 name since 2024
1 director
Documentsfilings and deeds
01-06-202660 days before the deadline
2025micro format
1 establishment registeredFirst year with figures

Key points

from the 2025 annual accounts

Turnover

≈ €470,000 estimated

The micro format states no turnover.

Debts

€468,999 92% of the balance sheet
Financial debts 34%Suppliers 7%Taxes and wages 5%Other 55%

Of this, €310,195 falls due within a year.

Position in the sector

€30,540

Higher net result than 80% of companies in retail trade. Sector median €4,755 · 25,291 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 320 companies had the same profile as WOLFS PHARMA has now. Each dot is one company, two years later.

96.6%
were still trading
2.5%
stopped another way
0.9%
went bankrupt
  • Micro
  • under 2 years old
  • solvency under 10%
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 320 companies, not a prediction for WOLFS PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 18-12-2024
  • 100 sharesdeed of 20-12-2024
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:1017566820
First establishment Rue Jean-Hermesse 45, Liège
Incorporation Founding capital of €10,000, 100 shares · Founded by (comparant) · appointed as sole director · published on 20-12-2024 · Gazette deed
All 4 events

Comparable companies

same main activity, similar in size and age
Company
WOLFS PHARMA Liège €509,540 €131,915 8.0% -
PHARMACIE JANSSEN Oupeye €518,745 €156,285 4.6% -
PHARMACIE BROMAN Montigny-le-Tilleul €481,857 €150,911 6.8% -
PHARMACIE DU PETIT MOULIN Seneffe €471,907 €114,484 4.9% -
Pharmacie Catherine Hardy Dinant €486,030 €161,826 -11.5% -
PHARMACIE DE BERLOZ Berloz €466,197 €129,768 25.9% -
PHARMACIE DELVA Brussels €437,107 €104,836 11.8% -

These companies have the same main activity as WOLFS PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €437,000 and €519,000, founded between 2023 and 2025.

Official details

Source: KBO
Status
Active since 18-12-2024Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment unit
2.367.942.7194020 Liège, since 01-01-2025
Financial year end
31 December
Peppol
Reachable since 05-11-2025
Company details

Annual accounts 2025

€509,540
Employeeson 31-12-2025
3
Filing
Filed on 01-06-2026, 60 days before the end of the filing period
Financials

Insights on WOLFS PHARMA

WOLFS PHARMA has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €40,540 and a net result of €30,540.

Its solvency ranks better than 28% of 25,320 sector peers (NACE 47) in financial year 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about WOLFS PHARMA

What is the company number of WOLFS PHARMA?
The company number of WOLFS PHARMA is 1017.566.820. The VAT number is the same number with BE in front: BE 1017.566.820.
Where is WOLFS PHARMA based?
The registered office is at Rue Jean-Hermesse 45, 4020 Liège.Company details
What does WOLFS PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of WOLFS PHARMA?
WOLFS PHARMA is a private limited company (BV).
When was WOLFS PHARMA founded?
WOLFS PHARMA was founded on 18-12-2024.
Is WOLFS PHARMA still active?
Yes, WOLFS PHARMA is an active enterprise in the KBO register.
How many employees does WOLFS PHARMA have?
WOLFS PHARMA had an average of 1.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does WOLFS PHARMA fall under?
In its 2025 annual accounts, WOLFS PHARMA states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of WOLFS PHARMA?
The turnover in financial year 2025 is ≈ €470,000. This figure is estimated from the gross margin of €131,915 and 38 comparable companies (NACE 477). It probably lies between €350,000 and €770,000.
Is WOLFS PHARMA profitable?
In financial year 2025, WOLFS PHARMA made a profit of €30,540.
Where can I find the annual accounts of WOLFS PHARMA?
WOLFS PHARMA filed 1 annual account with the National Bank of Belgium, for financial year 2025.

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.